Orgenesis Stock News

GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene

Orgenesis, Inc. (NASDAQ:ORGS ) Q2 2022 Earnings Conference Call August 16, 2022 11:00 AM ET Company Participants David Waldman – Investor Relations Vered Caplan – Chief Executive Officer Neil Reit

Orgenesis (NASDAQ:ORGS) Inc announced second-quarter 2022 revenue of $7.2 million and provided a business update for the period ending June 30, 2022. The global biotech company also said it secured a

GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene

Orgenesis (NASDAQ:ORGS) Inc, the global biotech company working to unlock the full potential of cell and gene therapies, has said it is entering the second phase of its POCare Platform rollout, and ex

Orgenesis (NASDAQ:ORGS) Inc said that a consortium led by its subsidiary, MIDA Biotech, has won a 4-million-euro grant under the European Innovation Council Pathfinder Challenge Program which support

Orgenesis (NASDAQ:ORGS) Inc said it has entered into a definitive securities purchase agreement with certain investors for a private placement for which it expects to receive gross proceeds of approx

Orgenesis' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript

Orgenesis (NASDAQ:ORGS) Inc reported a more than four-fold increase in revenue in 2021 from a year earlier, thanks to growing uptake of its Point of Care (POCare) platform. For the 2021 financial y

Orgenesis (NASDAQ:ORGS) Inc said it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The milestone has

12:05pm: US markets trend downward US stocks continued to plummet midday on Tuesday, as investors eyed earnings reports from some major corporates and fretted over looming interest rate rises. At noon

Orgenesis (NASDAQ:ORGS) Inc announced the next phase of collaboration with Johns Hopkins University, which involves the construction of a cell and gene therapy processing facility for point of care (P

Orgenesis Inc (ORGS) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $59M. The stock is currently down 14.9% year-to-date, down 52.7% over the past 12 months, and up 390.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 33.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -693.7% The company's stock price performance over the past 12 months lags the peer average by 250.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Orgenesis Inc (ORGS) shares closed today at 1.6% above its 52 week low of $2.55, giving the company a market cap of $62M. The stock is currently down 10.1% year-to-date, down 47.0% over the past 12 months, and up 418.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 8.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.9% lower than its 5-day moving average, 10.8% lower than its 20-day moving average, and 37.0% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -644.3% The company's stock price performance over the past 12 months lags the peer average by 230.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Orgenesis (NASDAQ:ORGS) and Stealth BioTherapeutics (NASDAQ:MITO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Analyst Ratings This is a summary of current ratings for Orgenesis and Stealth BioTherapeutics, as provided []